1. TREATMENT OF TUBERCULOSIS TREATMENT OF TUBERCULOSIS REVATHY.V ROLL NO. 62

3. ANTI- TB DRUGS FIRST LINE SECOND LINE ISONIAZID THIOACETAZONE RIFAMPICIN PAS PYRAZINAMIDE ETHIONAMIDE ETHAMBUTOL CYCLOSERINE STREPTOMYCIN KANAMYCIN CAPREOMYCIN AMIKACIN NEWER DRUGS CIPROFLOXACIN OFLOXACIN CLARITHROMYCIN AZITHROMYCIN RIFABUTIN

5. CONVENTIONAL CHEMOTHERAPY ISONIAZID ALONG WITH ONE OR MORE BACTERIOSTATIC DRUGS DURATION: 18 MONTHS REGIMENS: DAILY REGIMENS INTERMITTENT REGIMENS

7. CHEMOTHERAPY AND DOTS REVATHY.V ROLL NO. 62 THENDRAL’06

9. TUBERCULOSIS CASE DEFINITIONS PULMONARY TUBERCULOSIS, SMEAR POSITIVE PULMONARY TUBERCULOSIS, SMEAR NEGATIVE EXTRA PULMONARY TUBERCULOSIS TYPE OF PATIENTS NEW RELAPSE TRANSFERRED IN TREATMENT AFTER DEFAULT FAILURE CHRONIC OTHERS

10. TREATMENT OUTCOME CURED TREATMENT COMPLETED DIED FAILURE DEFAULTED TRANSFERRED OUT

11. TREATMENT REGIMEN CATEGORY I (RED BOX) INDICATIONS NEW SPUTUM SMEAR POSITIVE SERIOUSLY ILL SPUTUM SMEAR- NEGATIVE SERIOUSLY ILL EXTRA- PULMONARY REGIMEN 2(HRZE) 3 4(HR)3 PREPARATION : PATIENT WISE BOXES IP POUCH : 24 SINGLE DAY STRIPS CP POUCH : 18 WEEKLY BLISTERS

13. CATEGORY II (BLUE BOX) INDICATIONS SPUTUM SMEAR- POSITIVE RELAPSE FAILURE TREATMENT AFTER DEFAULT REGIMEN: 2(HRZES) 3 1(HRZE)3 5(HRE)3 PREPARATION: PATIENT WISE BOXES IP POUCH : 36 SINGLE DAY STRIPS WITH 24 SM VIALS CP POUCH : 22 WEEKLY BLISTERS

14. CATEGORY III (GREEN BOX) INDICATIONS NEW SPUTUM SMEAR NEGATIVE , NOT SERIOUSLY ILL NEW EXTRA-PULMONARY, NOT SERIOUSLY ILL REGIMEN: 2(HRZ)3 4(HR)3 PREPARATION: IP POUCH : 24 SINGLE DAY STRIPS CP POUCH : 18 WEEKLY BLISTERS

15. DOSAGE  PATIENTS WHO WEIGH 60 KG OR MORE – EXTRA I50 MG OF RIFAMPICIN GIVEN  PATIENTS OVER 50 YEARS OF AGE ARE GIVEN 500MG OF STREPTOMYCIN DRUG DOSE ISONIAZID 600 mg RIFAMPICIN 450 mg  PYRAZINAMIDE 1500 mg ETHAMBUTOL 1200 mg STREPTOMYCIN 750 mg 

16. PAEDIATRIC DOSAGE

17. MODE OF ADMINISTRATION: IP : THRICE WEEKLY(MON, WED, FRI OR TUE, THU OR SAT) EACH DOSE UNDER DIRECT OBSERVATION CP : THRICE WEEKLY (MON, WED, FRI OR TUE, THURS OR SAT) FIRST DOSE OF THE WEEK UNDER DIRECT OBSERVATION FOLLOW UP SPUTUM EXAMINATION SCHEDULE FIRST FOLLOW UP – AT THE END OF INTENSIVE PHASE IN ALL CATEGORIES SECOND FOLLOW UP – 2 MONTHS AFTER STARTING CONTINUOUS PHASE FINAL FOLLOW UP – AT THE END OF TREATMENT

18. FOLLOW UP SPUTUM EXAMINATION SCHEDULE CAT I 0 2 4 6 + NEG NEG NEG 0 2 3 5 7 + + NEG NEG NEG 0 2 3 5 7 + + + NEG NEG

19. ADVERSE REACTIONS REACTIONS DRUG RESPONSIBLE RENAL FAILURE,SHOCK, THROMBOCYTOPENIA RIFAMPICIN HEPATITIS PYRAZINAMIDE VISUAL DISTURBANCE ETHAMBUTOL HEARING LOSS, DISTURBED BALANCE STREPTOMYCIN SEVERE RASH, AGRANULOCYTOSIS THIOACETAZONE

20. TREATMENT UNDER SPECIAL CLINICAL SITUATIONS HOSPITALIZATION EXTREMELY ILL TUBERCULOUS MENINGITIS DURATION- 8 -9 MONTHS STEROIDS GIVEN PREGNANT WOMEN STREPTOMYCIN IS CONTRAINDICATED WOMEN ON OCPs INCREASE THE DOSAGE OF OCP OR SWITCH OVER TO OTHER METHODS HEPATOTOXICITY OR HEPATIC DISEASE H, R, Z SHOULD BE AVOIDED

21. HIV-TB SERIOUSLY ILL HIV STATUS SHOULD NOT BE MENTIONED IN ANY RECORDS CAT I REGIMEN SHOULD BE FIRST TREATED UNDER DOTS IF CD4 COUNT IS VERY LOW, REPLACE NEVIRAPINE WITH EFAVIRENZ

22. MDR-TB ATLEAST RESISTANT TO INH AND RIFAMPICIN TREATMENT BASED ON DOTS – PLUS DOTS- PLUS(CAT IV) INTENSIVE PHASE 6-9 MONTHS KANAMYCIN OFLOXACIN CYCLOSERINE ETHIONAMIDE ETHAMBUTOL PYRAZINAMIDE CONTINUATION PHASE 18 MONTHS OFLOXACIN CYCLOSERINE ETHIONAMIDE ETHAMBUTOL

23. XDR-TB RESISTANT TO RIFAMPICIN AND INH(MDR-TB) FLUROQUINOLONE 1 OR MORE OF SECOND LINE INJECTABLE DRUGS

24. ACTION FOR PATIENTS WHO INTERRUPT TREATMENT VISIT SHOULD BE MADE TO THE PATIENT’S HOME WITHIN 24 HOURS IN INTENSIVE PHASE WITHIN 7 DAYS IN CONTINUATION OHASE

26. A CHILD AGED 6 YEARS IS FOUND TO BE TUBERCULIN POSITIVE. HE WAS ALREADY VACCINATED FOR BCG. THERE IS ALSO CONTACT OF TUBERCULOSIS. YOU WANT TO FIND IF THE POSITIVITY IS DUE TO BCG VACCINATION OR LATENT TB. HOW WILL YOU FIND?

27. INTERFERON GAMMA ASSAY